| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Ben Gil Price last filed a Form 4 in November 2021, as Director at SRPT. The filings on record cover 2 companies. Ben Gil Price's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 42,830 shares of SRPT. Net of sales, the SRPT filings show accumulation of 4,500 shares.
Ben Gil Price has 7 Form 4 filings on record from February 2015 to November 2021, across 3 companies: CEO and President at MetaVia (MTVA), 2021; Director at Opus Genetics (IRD), 2018–2019; Director at Sarepta Therapeutics (SRPT), 2015–2016.
The 9 reported transactions were 5 option or other derivative awards, 2 open-market purchases and 2 stock awards.
Counted by filing, the open-market trades come to 2 purchases worth about $84K and no sales.
The largest open-market purchase was 4,500 shares of SRPT at an average $16.70 on March 14, 2016, about $75K.
Shares as reported in the last Form 4 for each company; the most recent is from November 2021. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.